PredictAD software promises early diagnosis of Alzheimer’s
Scientists at VTT Technical Research Centre in Finland have developed new software called PredictAD that could significantly boost the early diagnosis of Alzheimer's disease.
The comparative software contrasts patient’s measurements with those of other patients kept in large databases, then visualizes the status of the patient with an index and graphics.
Sick of Ads?
New Atlas Plus offers subscribers an ad free experience.
It's just US$19 a year.More Information
The support system and imaging methods were developed by VTT and Imperial College London.
The researchers used material compiled in the U.S. by the Alzheimer’s Disease Neuroimaging Initiative based on the records of 288 patients with memory problems. Nearly half of them, or 140 individuals, were diagnosed with Alzheimer’s disease on average 21 months after the initial measurements, which is about the same as the current European average of 20 months.
The researchers concluded that half of the patients could have been diagnosed with the disease around a year earlier, or nine months after the initial measurements. They say the accuracy of the predictions was comparable to clinical diagnosis.
There are several advantages of an early diagnosis of Alzheimer's. It can delay institutionalization and slow down the progress of the disease. It is also advantageous from the clinical trials perspective because if patients caught early can be included in the trials, treatment is likely to be more effective.
Working towards the same goal, researchers at Lancaster University in the U.K. recently developed an eye test method to detect early signs of Alzheimer’s.
The VTT researchers will spend the next five years carrying out the test at memory clinics in Europe. They also hope to expand its scope to include other illnesses that cause dementia. According to 2010 figures, an estimated 35.6 people live with dementia worldwide, and that number is expected to rise to 65.7 million by 2030.
The findings of the research were published in the Journal of Alzheimer’s Disease in November 2012. VTT cooperated with the University of Eastern Finland and Copenhagen University Hospital Rigshospitalet on this project.